Skip to main content
main-content

Medication

Adverse effects

09-04-2020 | Canagliflozin | News

FDA removes amputation Boxed Warning from canagliflozin label

Click through to read more on this announcement

09-02-2020 | Canagliflozin | News

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

08-28-2020 | Metformin | News

Early risk for anemia associated with metformin use in type 2 diabetes

Metformin consistently causes an early reduction in hemoglobin and increases the risk for moderate anemia in patients with type 2 diabetes, a MASTERMIND consortium analysis shows.

08-19-2020 | SGLT2 inhibitors | News

Data reject SLGT2 inhibitor link to increased amputation risk

The risk for lower limb amputation is not significantly increased among people using SGLT2 inhibitors to treat type 2 diabetes, according to findings from two studies.

08-14-2020 | Dapagliflozin | News

Dapagliflozin not linked to adverse limb events in DECLARE-TIMI 58

Dapagliflozin reduces the risk for cardiovascular events in people with type 2 diabetes, including those with peripheral artery disease, without increasing the risk for adverse limb events, show DECLARE-TIMI 58 data.

08-07-2020 | Adverse effects | News

Case of canagliflozin-triggered rosuvastatin-induced myotoxicity reported

Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.

02-06-2020 | Rosiglitazone | News

Individual patient data analysis firms up rosiglitazone safety verdict

An individual patient data meta-analysis confirms the increased heart failure risk associated with rosiglitazone and lends some support to an elevated myocardial infarction risk.

08-23-2019 | Canagliflozin | Highlight | News

CANVAS canagliflozin fracture effect may be chance finding

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

07-29-2019 | SGLT2 inhibitors | Highlight | News

Real-world data reassure on severe UTI risk with SGLT2 inhibition

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

05-22-2019 | Sulfonylureas | Editorial | Article

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

05-06-2019 | SGLT2 inhibitors | Highlight | News

Postmarketing data support Fournier gangrene link with SGLT2 inhibitors

Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

11-28-2018 | SGLT2 inhibitors | Commentary | Article

What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

11-14-2018 | SGLT2 inhibitors | News

Registry study supports SGLT2 inhibitor amputation risk

A registry study in The BMJ finds a small but significant increased risk for amputations in patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors.

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Image Credits